Navigation Links
Abbott to Preview New CELL-DYN(R) Emerald(TM) Hematology Instrument
Date:7/28/2008

CELL-DYN Emerald Designed to Deliver Quick, Reliable Results for Small to

Mid-Sized Laboratories

WASHINGTON, July 28 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) will preview an upcoming addition to the CELL-DYN(R) family of hematology instruments, the Emerald(TM), at the American Association of Clinical Chemistry (AACC) Annual Meeting this week. The Emerald is designed to be a valuable tool for performing complete blood counts (CBCs) -- a test frequently ordered by doctors to assess a patient's overall health and to screen for a variety of disorders such as anemia and infection. The Emerald has the ability to complete CBC results in 60 seconds and report results in easy-to-read histograms representing white blood cells, red blood cells and platelets.

Expected to be available in the United States by the end of the year, subject to regulatory clearance, the Emerald will expand Abbott's hematology platform by offering a premium, robust low-volume solution for small to mid-sized clinical laboratories. Enhanced technology combined with intuitive software and onboard reagents enable the Emerald to offer reliable performance while promoting faster and simpler data entry.

As low to medium-volume hospital laboratories and clinics continue to seek greater efficiency under tight space limitations, the Emerald is expected to deliver reliable, productivity-enhancing performance in a small footprint.

The AACC Annual Meeting is a global meeting that attracts nearly 20,000 attendees from more than 100 countries. The Emerald is on display in Abbott's AACC exhibit booth (No. 1507).

About CELL-DYN

Abbott's CELL-DYN family of hematology instruments is well known for its efficiency and ability to provide fast access to patient results. Instruments range from larger analyzers that process a high number of patient samples to smaller instruments designed for medium and small-volume facilities. Besides supplying standard CBC results, some instruments have additional features to aid in the evaluation of more complex disease states or infections including cancer, HIV and a variety of anemias.

About Abbott's Diagnostics Businesses

Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices and clinics. With more than 65,000 customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnosis from an art to a science through the company's commitment to improving patient care and lowering costs. Abbott's history is filled with examples of first-of-a-kind diagnostic products and significant technological and research advancements.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could ... after surgery, though activity levels decline over time. The study, presented today at ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... why concussion rates are on the rise, say researchers presenting their work at ... Toronto, Ontario, Canada. , “The combination of evaluating the patterns of change in ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
(Date:7/20/2017)... NY, July 20, 2017 (PRWEB) , ... ... ... Nastel Technologies, a global provider of enterprise-grade IT operations analytics and application ... arm of one of world’s largest healthcare services providers. , According to ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended ... The adjustable beds used in such facilities are specially designed to accommodate patients with ... support. , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... a clinical-stage pharmaceutical company focused on the development of oral ... from the Israel Securities Authority to dual-list its common stock ... will commence trading on the TASE on July 12, 2017 ... of the Company, it is expected that Oramed will be ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
(Date:6/30/2017)... In vitro diagnostics market firm Kalorama Information ... least ten diagnostic companies have successfully completed financings.  The ... a loan facility.  The size of these financings ranged ... Information provides a monthly IVD Market Trends Report ... "Diagnostics deals ...
Breaking Medicine Technology: